Precigen Inc. (PGEN) shares reached a 52-week high of $7.74 and traded at $7.83 as of midmorning on Wednesday, extending a sharp rally that has seen the biotechnology company post a 110% gain over six months and a 95.66% appreciation over the trailing year.
The momentum followed second-quarter 2026 financial results that showed the company swinging to profitability, reporting earnings per share of $0.05 against an analyst consensus expectation of a $0.01 loss. Revenue came in at $54.98 million, nearly double the $27.83 million estimate, and net income for the quarter totaled $20.1 million.
InvestingPro attributed the strong performance largely to early demand for PAPZIMEOS, the company’s approved gene therapy for adult recurrent respiratory papillomatosis. While Precigen posted a combined loss over the trailing twelve months, analysts surveyed by InvestingPro anticipate profitability for the current year.
The same analysis noted that the stock is currently trading above its estimated fair value, though it remains categorized as one to watch.
The results were published on September 17, 2026.
